Stimulating the motivation of patients with residual unilateral arm paresis after stroke to increase arm activity in the home setting using a digital application

Stimulating the motivation of patients with residual unilateral arm paresis after stroke to increase arm activity in the home setting using a digital application - ADA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00027571

Enrollment

Registered

2022-01-07

Start date

2022-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G81 G45 I60 I61 I62 I63 I64

Interventions

Group 1: Application of the ARYS me system consisting of smartphone app and tracker in addition to care as usual. Group 2: Care as usual

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Residual unilateral arm paresis with one of the listed diagnoses; Completion of acute inpatient treatment and discharge to home for home care or completion of acute inpatient treatment and provision of follow-up treatment followed by discharge to home and home care; Internet-enabled smartphone or tablet with Android (Android 6.0 or higher) or iOS (iOS 11.0 or higher) operating system; Written informed consent regarding study participation and data processing; Ability to speak and understand German; Ability to don the ARYS tracker independently or with the assistance of a relative/caregiver; Physical and cognitive ability to operate the ARYS me app and the ARYS tracker.

Exclusion criteria

Exclusion criteria: Patients participating in other interventional studies; Patients who are in a dependent/employee relationship with the sponsor or investigator; Patients in institutionalization due to court or regulatory order; Patients with schizophrenia (F20), schizoaffective disorder (F25), bipolar affective disorder (F31), intracranial injury (S06), open skin lesions, or skin irritation at the wrist of the paretic arm; Patients who continue treatment in an inpatient care facility after completion of acute inpatient treatment.

Design outcomes

Primary

Measure	Time frame
The ARYS™ me digital application results in greater improvement in paretic arm use between time t0 (baseline) and t2 (post-treatment) according to the Amount of Use (AOU) subscale of the Motor Activity Log - 14 (MAL-14) compared to the control group.	—

Secondary

Measure	Time frame
In addition, the secondary endpoints quality of paretic arm use movements (MAL-14 Quality of Movement; QOM), quality of life (Euro Quality of Life 5 Dimension 5 Level; EQ-5D-5L), participation and involvement (Index to Measure Limitations of Participation; IMET), patient autonomy (General Self-Efficacy Short Scale; ASKU), finger dexterity (Nine-Hole Peg Test; NHPT), and manual skills (ABILHAND) will be assessed in the same way.	—

Measure

Time frame

In addition, the secondary endpoints quality of paretic arm use movements (MAL-14 Quality of Movement; QOM), quality of life (Euro Quality of Life 5 Dimension 5 Level; EQ-5D-5L), participation and involvement (Index to Measure Limitations of Participation; IMET), patient autonomy (General Self-Efficacy Short Scale; ASKU), finger dexterity (Nine-Hole Peg Test; NHPT), and manual skills (ABILHAND) will be assessed in the same way.

—

Countries

Germany

Contacts

Public ContactBirgit Freyberg-Hanl

BG Klinikum Bergmannstrost Halle

arys@bergmannstrost.de+49 345 13260

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026